Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Madrigal Pharmaceuticals Inc
(NQ:
MDGL
)
193.33
-1.05 (-0.54%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Apr 26, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Madrigal Pharmaceuticals Inc
< Previous
1
2
3
4
5
6
Next >
12 Health Care Stocks Moving In Monday's Pre-Market Session
December 19, 2022
Via
Benzinga
Madrigal Shares Skyrocket After Successful NASH Study
December 19, 2022
Via
Benzinga
Tesla, Amazon, Madrigal Pharma, Pfizer, Synaptogenix: Why These 5 Stocks Are Drawing Investors' Attention Today
December 18, 2022
Major Wall Street indices had closed in the red on Friday in the wake of a continued sell-off following the hawkish stance asserted by the Federal Reserve. Friday witnessed volatile trading as a large...
Via
Benzinga
2 Healthcare Stocks Poised to Rocket Higher in the 4th Quarter
November 06, 2022
These two healthcare stocks could deliver market-crushing gains by year's end.
Via
The Motley Fool
Madrigal Pharmaceuticals: Q3 Earnings Insights
November 03, 2022
Madrigal Pharmaceuticals (NASDAQ:MDGL) reported its Q3 earnings results on Thursday, November 3, 2022 at 08:00 AM. Here's what investors need to know about the announcement.
Via
Benzinga
10 Health Care Stocks Whale Activity In Today's Session
October 28, 2022
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity...
Via
Benzinga
Analysts Believe Madrigal's Resmetirom Shows Impressive Overall Profile In Liver Fibrosis
June 27, 2022
Via
Benzinga
Recap: Madrigal Pharmaceuticals Q1 Earnings
May 09, 2022
Madrigal Pharmaceuticals (NASDAQ:MDGL) reported its Q1 earnings results on Monday, May 9, 2022 at 06:00 AM. Here's what investors need to know about the announcement.
Via
Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
October 25, 2022
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity...
Via
Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
October 17, 2022
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 8, 2022
July 08, 2022
Via
Benzinga
Madrigal Pharma's Kidney Disease Candidate Improves Liver, Cardiovascular Health
January 31, 2022
Madrigal Pharmaceuticals Inc (NASDAQ: MDGL) has
Via
Benzinga
The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline
August 18, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 17) AbbVie Inc. (NYSE: ABBV)...
Via
Benzinga
Exposures
Product Safety
The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business
August 17, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 16) Bio-Rad Laboratories, Inc...
Via
Benzinga
Bear Market Rally Lifts HealthCare Stocks Off Bottom
June 22, 2022
Clearly we are in a biotech bear market with both diagnostics and vaccine revenues stalled. If gene editing stocks cannot offer breakthrough clinical news then stick with large cap biopharma.
Via
Talk Markets
Madrigal Announces Debt Funding Of $250M To Back Potential US Resmetirom Launch
May 09, 2022
Via
Benzinga
Tough Slogging Ahead for Investors, Diversification is Important
March 07, 2022
Speculative small/mid-cap biotech stocks hit new lows this past week with the XBI at a “triple bottom” about the $84 level only 10 points above the March 2020 lows.
Via
Talk Markets
Madrigal Pharmaceuticals: A "Best in Class" Biotech Buy
February 17, 2022
One of the few broadly positive binary events in biotechnology of late, Madrigal’s best-in-class NASH compound is well on its way with de-risked, late-stage clinical results.
Via
Talk Markets
Bear Market Bets In Biotech
February 07, 2022
Taken together, the SPDR S&P Biotech ETF easily broke below the long-term 200-week support for the first time since the pandemic originally hit the markets in March of 2020.
Via
Talk Markets
Earnings Scheduled For May 9, 2022
May 09, 2022
Companies Reporting Before The Bell • Atlantica Sustainable (NASDAQ:AY) is likely to report quarterly loss at $0.08 per share on revenue of $277.90 million.
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
February 03, 2022
Gainers SOC Telemed (NASDAQ:TLMD) shares increased by 333.5% to $2.79 during Thursday's regular session. Trading volume for this security as of 12:30 EST is 19.4...
Via
Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
January 31, 2022
Gainers Madrigal Pharmaceuticals (NASDAQ:MDGL) shares rose 14.9% to $64.8 during Monday's pre-market session. The market value of their outstanding shares is at $1.1...
Via
Benzinga
Top Picks For 2022: Madrigal Pharmaceuticals
January 22, 2022
Madrigal Pharmaceuticals is poised to deliver positive Phase III data in 2022 for resmetirom, its best-in-class NASH (nonalcoholic steatohepatitis) compound.
Via
Talk Markets
Benzinga's Top Ratings Upgrades, Downgrades For October 7, 2021
October 07, 2021
Upgrades For State Street Corporation (NYSE:
Via
Benzinga
The Daily Biotech Pulse: Takeda Suspends Studies On Safety Scare, Acer's Sleep Disorder Drug Filing Accepted For Review, Voyager's Licensing Options Deal
October 06, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 5) Bicycle Therapeutics plc (...
Via
Benzinga
The Daily Biotech Pulse: Aprea Jumps On ESMO Presentation, Verrica Sinks On Regulatory Setback, Aerie CEO Quits, J&J Touts Positive COVID-19 Booster Shot Data
September 21, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 20) Cerevel Therapeutics...
Via
Benzinga
Exposures
COVID-19
The Daily Biotech Pulse: Adcom Tryst For Pfizer/BioNTech Booster Shot, AbCellera's COVID Antibody Treatment Gets Expanded Use, Protagonist Slapped With Clinical Hold
September 17, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 16) Bicycle Therapeutics plc (...
Via
Benzinga
The Daily Biotech Pulse: ProQR-Lilly R&D Partnership, Sanofi's Pemphigus Trial Disappointment, Humanigen's COVID-19 Drug Denied Emergency Use Authorization
September 09, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 8) Abbott Laboratories (NYSE:...
Via
Benzinga
Exposures
COVID-19
The Daily Biotech Pulse: J&J Announces CEO Transition, FibroGen's Roxadustat Approved In Europe, GeoVax, Sorrento Announce COVID-19 Vaccine Data
August 20, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 19) Alkermes plc (NASDAQ: ALKS...
Via
Benzinga
Exposures
COVID-19
The Daily Biotech Pulse: Coherus Soars On Lung Cancer Data, Illumina Closes On Grail Buy Without Regulatory Clearance, Adagene Strikes Collaboration With Merck
August 19, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 18) AbbVie Inc. (NYSE: ABBV)...
Via
Benzinga
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.